ReviewBritish journal of pharmacology2011
The GABAβ receptor as a target for antidepressant drug action.
Review in British journal of pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 84 citations in OpenAlex.
- NAcLat-DBS reduces GABANeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Exploring Molecular Mechanism of Fluoxetine in Animal Models of Depression via Integrated Metabolomic and Proteomic Analysis.Journal of cellular and molecular medicine · 2026Article
- Tea and Its Active Ingredients in Preventing and Alleviating Depression: A Comprehensive Review.Foods (Basel, Switzerland) · 2025Review
- Presynaptic hyperexcitability reversed by positive allosteric modulation of a GABABR epilepsy variant.Brain : a journal of neurology · 2025Article
- Exploration of neural mechanisms underlying antidepressant-like property ofCurrent research in physiology · 2025Article
- Biosynthesis of Gamma-Aminobutyric Acid (GABA) byCurrent issues in molecular biology · 2023Review
- Peripheral modulation of antidepressant targets MAO-B and GABAAR by harmol induces mitohormesis and delays aging in preclinical models.Nature communications · 2023Article
- Autism spectrum disorder in the fragile X premutation state: possible mechanisms and implications.Journal of neurology · 2022Review
- Proteomic analysis of human hippocampal subfields provides new insights into the pathogenesis of Alzheimer's disease and the role of glial cells.Brain pathology (Zurich, Switzerland) · 2022Article
- Neuroanatomical, Biochemical, and Functional Modifications in Brain Induced by Treatment with Antidepressants.Molecular neurobiology · 2022Review
- GABACurrent topics in behavioral neurosciences · 2022Article
- Multiregional profiling of the brain transmembrane proteome uncovers novel regulators of depression.Science advances · 2021Article
- Hippocampal subfield transcriptome analysis in schizophrenia psychosis.Molecular psychiatry · 2021Article
- Molecular mechanisms of metabotropic GABAScience advances · 2021Review
- The GABAMolecules (Basel, Switzerland) · 2020Review
- Altered motor system function in post-concussion syndrome as assessed via transcranial magnetic stimulation.Clinical neurophysiology practice · 2020Article
- Sex differences in gene expression with galactosylceramide treatment in Cln3Δex7/8 mice.PloS one · 2020Article
- In Silico Methods for the Discovery of Orthosteric GABAMolecules (Basel, Switzerland) · 2019Article
- GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia.Acta pharmacologica Sinica · 2018Review
- Neural mechanisms underlying GABAergic regulation of adult hippocampal neurogenesis.Cell and tissue research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Preclinical and clinical data suggest that a modification in GABA(B) receptor expression and function may contribute to the symptoms of major depression and the response to antidepressants. This includes laboratory animal experiments demonstrating that antidepressants modify brain GABA(B) receptor expression and function and that GABA(B) receptor antagonists display antidepressant potential in animal models of this condition. Clinical and post-mortem studies reveal changes in GABAergic transmission associated with depression as well as depression-related changes in GABA(B) subunit expression that are localized to the cortical depression network. Detailed in this review are the preclinical and clinical data implicating a role for the GABA(B) receptor system in mediating symptoms of this disorder and its possible involvement in the response to antidepressants. Particular emphasis is placed on clinical and post-mortem studies, including previously unpublished work demonstrating regionally-selective modifications in GABA(B) receptor subunit expression in brain samples obtained from depressed subjects. Together with the earlier preclinical studies, these new data point to a role for the GABA(B) system in major depression and support the antidepressant potential of GABA(B) receptor antagonists.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.